Gemma Pidelaserra Martí

Gemma Pidelaserra Martí

Auto-generated profile, based on publicly available information

Gemma Pidelaserra Martí

Research Group Mechanisms of Oncolytic Immunotherapy, Clinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany; Faculty of Biosciences, Heidelberg University and Helmholtz International Graduate School for Cancer Research, DKFZ, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2018 in Science Immunology
Verified
Journal Article
Closed access
PDF file
RMRajagopal Murugan
Rajagopal Murugan
LBLisa Buchauer
Lisa Buchauer
GTGianna Triller
Gianna Triller
CKCornelia Kreschel
Cornelia Kreschel
GCGiulia Costa
Giulia Costa
HWHedda Wardemann
Hedda Wardemann
Affinity maturation, the clonal selection and expansion of antigen-activated B cells expressing somatically mutated antibody variants that develop during T cell–dependent germinal center reactions, is considered pivotal for efficient development of protective B cell memory responses to infection and vaccination. Repeated antigen exposure promotes affinity maturation but each time also recruits antigen-reactive naïve B cells into the response. Here, we determined the relative impact of affinity maturation versus antigen-mediated clonal selection of naïve B cells to mount potent B cell memory responses in humans after repeated exposure to a complex pathogen, the malaria parasite Plasmodium falciparum (Pf). Using single-cell immunoglobulin (Ig) gene sequencing and production of recombinant monoclonal antibodies, we analyzed the origin, development, and quality of memory B cell responses to Pf circumsporozoite protein (PfCSP), the major sporozoite surface protein. We show that after repeated immunization of Pf-naïve volunteers with infectious Pf sporozoites (PfSPZ Challenge) under chloroquine prophylaxis (PfSPZ-CVac), the clonal selection of potent germline and memory B cell precursors against the central PfCSP NANP repeat outpaces affinity maturation because the majority of Ig gene mutations are affinity-neutral. Mathematical modeling explains how the efficiency of affinity maturation decreases strongly with antigen complexity. Thus, in the absence of long-term exposure, the frequency of antigen-reactive precursors and likelihood of their activation rather than affinity maturation will determine the quality of anti-PfCSP memory B cell responses. These findings have wide implications for the design of vaccination strategies to induce potent B cell memory responses against PfCSP and presumably other structurally complex antigens.

22 June 2018 in Science
Verified
Journal Article
Open access
PDF file
KIKatharina Imkeller
Katharina Imkeller
SSStephen W. Scally
Stephen W. Scally
ABAlexandre Bosch
Alexandre Bosch
GMGemma Pidelaserra Martí
Gemma Pidelaserra Martí
GCGiulia Costa
Giulia Costa
HWHedda Wardemann
Hedda Wardemann
Surface antibody maturation: Affinity maturation in B cells generates antibodies with increasingly enhanced antigen-binding properties. Imkeller et al. investigated the maturation of human B cells that express protective antibodies against the circumsporozoite protein of the malaria-causing parasite Plasmodium falciparum (PfCSP). The repetitive structure of PfCSP induces mutations in B cells, facilitating direct interactions between two repeat-bound antibodies against PfCSP, which enhance antigen affinity and B cell activation. Such interactions may optimize binding and promote clustering of surface antibodies in general. Science , this issue p. 1358

1 December 2020 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Open access
GPGemma Pidelaserra-Martí
Gemma Pidelaserra-Martí
CEChristine Engeland
Christine Engeland
The study of measles virus (MeV) as a cancer immunotherapeutic was prompted by clinical observations of leukemia and lymphoma regressions in patients following measles virus infection in the 1970s and 1980s. Since then, numerous preclinical studies have confirmed the oncolytic activity of MeV vaccine strains as well as their potential to promote long-lasting tumor-specific immune responses. Early clinical data indicate that some of these effects may translate to the treatment of cancer patients. In this review, we provide a structured summary of current evidence for the anti-tumor immune activity of oncolytic MeV. We start with an overview of MeV oncolysis and MeV-induced immunogenic cell death. Next, we relate findings on MeV-mediated activation of antigen-presenting cells, T cell priming and effector mechanisms to the cancer immunity cycle. We discuss additional factors in the tumor microenvironment which are modulated by MeV treatment as well as the role of anti-viral immunity. Based on these findings, we highlight avenues for rational enhancement of oncolytic MeV immunotherapy by vector engineering. We further point to advantages and drawbacks of experimental models and propose areas warranting promising research. Lastly, we review the available immunomonitoring data from several Phase I clinical trials. While this review presents data for MeV, the concepts and principles introduced herein apply to other oncolytic viruses, providing a framework to assess novel cancer immunotherapies.

21 February 2020 in Viruses
Verified
Journal Article
Open access
PDF file
EBElena Busch
Elena Busch
KKKristina D. Kubon
Kristina D. Kubon
JMJohanna K. M. Mayer
Johanna K. M. Mayer
GPGemma Pidelaserra-Martí
Gemma Pidelaserra-Martí
JAJessica Albert
Jessica Albert
CEChristine Engeland
Christine Engeland
Priming and activation of CD8+ T cell responses is crucial to achieve anti-viral and anti-tumor immunity. Live attenuated measles vaccine strains have been used successfully for immunization for decades and are currently investigated in trials of oncolytic virotherapy. The available reverse genetics systems allow for insertion of additional genes, including heterologous antigens. Here, we designed recombinant measles vaccine vectors for priming and activation of antigen-specific CD8+ T cells. For proof-of-concept, we used cytotoxic T lymphocyte (CTL) lines specific for the melanoma-associated differentiation antigen tyrosinase-related protein-2 (TRP-2), or the model antigen chicken ovalbumin (OVA), respectively. We generated recombinant measles vaccine vectors with TRP-2 and OVA epitope cassette variants for expression of the full-length antigen or the respective immunodominant CD8+ epitope, with additional variants mediating secretion or proteasomal degradation of the epitope. We show that these recombinant measles virus vectors mediate varying levels of MHC class I (MHC-I)-restricted epitope presentation, leading to activation of cognate CTLs, as indicated by secretion of interferon-gamma (IFNγ) in vitro. Importantly, the recombinant OVA vaccines also mediate priming of naïve OT-I CD8+ T cells by dendritic cells. While all vaccine variants can prime and activate cognate T cells, IFNγ release was enhanced using a secreted epitope variant and a variant with epitope strings targeted to the proteasome. The principles presented in this study will facilitate the design of recombinant vaccines to elicit CD8+ responses against pathogens and tumor antigens.

16 October 2014 in Scandinavian Journal of Immunology
Verified
Journal Article
Closed access
PDF file
GMG. Pidelaserra Martí
G. Pidelaserra Martí
KMK. G. Isdahl Mohn
K. G. Isdahl Mohn
RCRebecca Jane Cox
Rebecca Jane Cox
Karl Albert BrokstadKarl Albert Brokstad
Karl Albert Brokstad